
Krystal Biotech is a biotechnology business based in the US. Krystal Biotech shares (KRYS) are listed on the NASDAQ and all prices are listed in US Dollars. Krystal Biotech employs 119 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Krystal Biotech stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – KRYS. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Krystal Biotech stock price (NASDAQ: KRYS)
Use our graph to track the performance of KRYS stocks over time.Krystal Biotech shares at a glance
Latest market close | $84.22 |
---|---|
52-week range | $47.67 - $85.65 |
50-day moving average | $77.56 |
200-day moving average | $70.33 |
Wall St. target price | $107.25 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-4.48 |
Buy Krystal Biotech stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Krystal Biotech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Krystal Biotech price performance over time
Historical closes compared with the close of $84.22 from 2023-01-27
1 week (2023-01-24) | 1.18% |
---|---|
1 month (2022-12-30) | 6.31% |
3 months (2022-10-31) | 10.09% |
6 months (2022-07-29) | 16.04% |
1 year (2022-01-28) | 56.66% |
---|---|
2 years (2021-01-29) | 20.83% |
3 years (2020-01-31) | 61.16% |
5 years (2018-01-30) | 738.84% |
Krystal Biotech financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -13.4% |
Return on equity TTM | -27.34% |
Profit margin | 0% |
Book value | $21.03 |
Market capitalisation | $2.2 billion |
TTM: trailing 12 months
Krystal Biotech share dividends
We're not expecting Krystal Biotech to pay a dividend over the next 12 months.
Krystal Biotech share price volatility
Over the last 12 months, Krystal Biotech's shares have ranged in value from as little as $47.67 up to $85.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Krystal Biotech's is 0.8762. This would suggest that Krystal Biotech's shares are less volatile than average (for this exchange).
Krystal Biotech overview
Krystal Biotech, Inc. , a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech in the news
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
Krystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDA
Frequently asked questions
What percentage of Krystal Biotech is owned by insiders or institutions?Currently 16.424% of Krystal Biotech shares are held by insiders and 82.325% by institutions. How many people work for Krystal Biotech?
Latest data suggests 119 work at Krystal Biotech. When does the fiscal year end for Krystal Biotech?
Krystal Biotech's fiscal year ends in December. Where is Krystal Biotech based?
Krystal Biotech's address is: 2100 Wharton Street, Pittsburgh, PA, United States, 15203 What is Krystal Biotech's ISIN number?
Krystal Biotech's international securities identification number is: US5011471027 What is Krystal Biotech's CUSIP number?
Krystal Biotech's Committee on Uniform Securities Identification Procedures number is: 501147102
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert